Immunology
| Zeile 471: | Zeile 471: | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=32587367|t=2020. Potential contribution of increased soluble IL-2R to lymphopenia in COVID-19 patients.|pdf=|usr=010}} | {{tp|p=32587367|t=2020. Potential contribution of increased soluble IL-2R to lymphopenia in COVID-19 patients.|pdf=|usr=010}} | ||
| − | + | ||
{{tp|p=32541836|t=2020. Systemically comparing host immunity between survived and deceased COVID-19 patients.|pdf=|usr=010}} | {{tp|p=32541836|t=2020. Systemically comparing host immunity between survived and deceased COVID-19 patients.|pdf=|usr=010}} | ||
{{tp|p=32553163|t=2020. Modulation of Extracellular ISG15 Signaling by Pathogens and Viral Effector Proteins.|pdf=|usr=010}} | {{tp|p=32553163|t=2020. Modulation of Extracellular ISG15 Signaling by Pathogens and Viral Effector Proteins.|pdf=|usr=010}} | ||
| − | + | ||
| − | + | ||
{{tp|p=32574709|t=2020. COVID-19 pneumonia: CD8(+) T and NK cells are decreased in number but compensatory increased in cytotoxic potential.|pdf=|usr=010}} | {{tp|p=32574709|t=2020. COVID-19 pneumonia: CD8(+) T and NK cells are decreased in number but compensatory increased in cytotoxic potential.|pdf=|usr=010}} | ||
{{tp|p=32578831|t=2020. Human Leukocyte Transcriptional Response to SARS-CoV-2 Infection.|pdf=|usr=010}} | {{tp|p=32578831|t=2020. Human Leukocyte Transcriptional Response to SARS-CoV-2 Infection.|pdf=|usr=010}} | ||
| − | + | ||
{{tp|p=32539816|t=2020. Response to "COVID-19: room for treating T cell exhaustion?"|pdf=|usr=010}} | {{tp|p=32539816|t=2020. Response to "COVID-19: room for treating T cell exhaustion?"|pdf=|usr=010}} | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=32583231|t=2020. Age-related decline of de novo T cell responsiveness as a cause of COVID-19 severity.|pdf=|usr=010}} | {{tp|p=32583231|t=2020. Age-related decline of de novo T cell responsiveness as a cause of COVID-19 severity.|pdf=|usr=010}} | ||
{{tp|p=32556942|t=2020. Severe COVID-19 and aging: are monocytes the key?|pdf=|usr=010}} | {{tp|p=32556942|t=2020. Severe COVID-19 and aging: are monocytes the key?|pdf=|usr=010}} | ||
| − | + | ||
{{tp|p=32569607|t=2020. Lymphopenia during the COVID-19 infection: What it shows and what can be learned.|pdf=|usr=010}} | {{tp|p=32569607|t=2020. Lymphopenia during the COVID-19 infection: What it shows and what can be learned.|pdf=|usr=010}} | ||
| − | + | ||
| − | + | ||
{{tp|p=32544911|t=2020. Strategies to Prevent SARS-CoV-2-Mediated Eosinophilic Disease in Association with COVID-19 Vaccination and Infection.|pdf=|usr=010}} | {{tp|p=32544911|t=2020. Strategies to Prevent SARS-CoV-2-Mediated Eosinophilic Disease in Association with COVID-19 Vaccination and Infection.|pdf=|usr=010}} | ||
{{tp|p=32585285|t=2020. Herd Immunity and Vaccination of children for COVID19.|pdf=|usr=010}} | {{tp|p=32585285|t=2020. Herd Immunity and Vaccination of children for COVID19.|pdf=|usr=010}} | ||
{{tp|p=32574694|t=2020. Relationship between Chest CT manifestations and immune response in COVID-19 patients.|pdf=|usr=010}} | {{tp|p=32574694|t=2020. Relationship between Chest CT manifestations and immune response in COVID-19 patients.|pdf=|usr=010}} | ||
| − | + | ||
{{tp|p=32572527|t=2020. SARS-CoV-2 viral loads and serum IgA/IgG immune responses in critically ill COVID-19 patients.|pdf=|usr=010}} | {{tp|p=32572527|t=2020. SARS-CoV-2 viral loads and serum IgA/IgG immune responses in critically ill COVID-19 patients.|pdf=|usr=010}} | ||
| − | + | ||
{{tp|p=32540792|t=2020. Eosinophil Response Against Classical and Emerging Respiratory Viruses: COVID-19.|pdf=|usr=010}} | {{tp|p=32540792|t=2020. Eosinophil Response Against Classical and Emerging Respiratory Viruses: COVID-19.|pdf=|usr=010}} | ||
{{tp|p=32540791|t=2020. Upper and Lower Airways Functional Examination in Asthma and Respiratory Allergic Deseases. Considerations in the SARS-CoV-2 Post-Pandemic Situation.|pdf=|usr=010}} | {{tp|p=32540791|t=2020. Upper and Lower Airways Functional Examination in Asthma and Respiratory Allergic Deseases. Considerations in the SARS-CoV-2 Post-Pandemic Situation.|pdf=|usr=010}} | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=32590062|t=2020. Out of the frying pan and into the fire? Due diligence warranted for ADE in COVID-19.|pdf=|usr=010}} | {{tp|p=32590062|t=2020. Out of the frying pan and into the fire? Due diligence warranted for ADE in COVID-19.|pdf=|usr=010}} | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=32581077|t=2020. COVID-19 Hyperinflammation: What about Neutrophils?|pdf=|usr=010}} | {{tp|p=32581077|t=2020. COVID-19 Hyperinflammation: What about Neutrophils?|pdf=|usr=010}} | ||
| − | + | ||
{{tp|p=32572247|t=2020. Sex differences in immune responses in COVID-19.|pdf=|usr=010}} | {{tp|p=32572247|t=2020. Sex differences in immune responses in COVID-19.|pdf=|usr=010}} | ||
{{tp|p=32572245|t=2020. Roles for eosinophils and basophils in COVID-19?|pdf=|usr=010}} | {{tp|p=32572245|t=2020. Roles for eosinophils and basophils in COVID-19?|pdf=|usr=010}} | ||
| − | + | ||
{{tp|p=32561873|t=2020. COVID-19 revisiting inflammatory pathways of arthritis.|pdf=|usr=010}} | {{tp|p=32561873|t=2020. COVID-19 revisiting inflammatory pathways of arthritis.|pdf=|usr=010}} | ||
| − | + | ||
{{tp|p=32589296|t=2020. COVID-19: A series of important recent clinical and laboratory reports in immunology and pathogenesis of SARS-CoV-2 infection and care of allergy patients.|pdf=|usr=010}} | {{tp|p=32589296|t=2020. COVID-19: A series of important recent clinical and laboratory reports in immunology and pathogenesis of SARS-CoV-2 infection and care of allergy patients.|pdf=|usr=010}} | ||
{{tp|p=32584441|t=2020. Immunology of COVID-19: mechanisms, clinical outcome, diagnostics and perspectives - a report of the European Academy of Allergy and Clinical Immunology (EAACI).|pdf=|usr=010}} | {{tp|p=32584441|t=2020. Immunology of COVID-19: mechanisms, clinical outcome, diagnostics and perspectives - a report of the European Academy of Allergy and Clinical Immunology (EAACI).|pdf=|usr=010}} | ||
| − | + | ||
{{tp|p=32579026|t=2020. COVID-19 Related Acute Respiratory Distress Syndrome: Not so Atypical.|pdf=|usr=010}} | {{tp|p=32579026|t=2020. COVID-19 Related Acute Respiratory Distress Syndrome: Not so Atypical.|pdf=|usr=010}} | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=32579477|t=2020. Platelets and Immunity: Going Viral.|pdf=|usr=010}} | {{tp|p=32579477|t=2020. Platelets and Immunity: Going Viral.|pdf=|usr=010}} | ||
{{tp|p=32578486|t=2020. Autophagy/virophagy: a "disposal strategy" to combat COVID-19.|pdf=|usr=010}} | {{tp|p=32578486|t=2020. Autophagy/virophagy: a "disposal strategy" to combat COVID-19.|pdf=|usr=010}} | ||
| − | + | ||
{{tp|p=32573711|t=2020. Platelet Gene Expression and Function in COVID-19 Patients.|pdf=|usr=010}} | {{tp|p=32573711|t=2020. Platelet Gene Expression and Function in COVID-19 Patients.|pdf=|usr=010}} | ||
| − | + | ||
| − | + | ||
{{tp|p=32592406|t=2020. Immune response in children with COVID-19 is characterized by lower levels of T cell activation than infected adults.|pdf=|usr=010}} | {{tp|p=32592406|t=2020. Immune response in children with COVID-19 is characterized by lower levels of T cell activation than infected adults.|pdf=|usr=010}} | ||
| − | + | ||
| − | + | ||
{{tp|p=32543971|t=2020. Increased CD4/CD8 ratio as a risk factor for critical illness in coronavirus disease 2019 (COVID-19): a retrospective multicentre study.|pdf=|usr=010}} | {{tp|p=32543971|t=2020. Increased CD4/CD8 ratio as a risk factor for critical illness in coronavirus disease 2019 (COVID-19): a retrospective multicentre study.|pdf=|usr=010}} | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=32544216|t=2020. COVID-19 and Crosstalk With the Hallmarks of Aging.|pdf=|usr=010}} | {{tp|p=32544216|t=2020. COVID-19 and Crosstalk With the Hallmarks of Aging.|pdf=|usr=010}} | ||
| − | + | ||
| − | + | ||
{{tp|p=32574708|t=2020. Mitochondria and Microbiota dysfunction in COVID-19 pathogenesis.|pdf=|usr=010}} | {{tp|p=32574708|t=2020. Mitochondria and Microbiota dysfunction in COVID-19 pathogenesis.|pdf=|usr=010}} | ||
{{tp|p=32591762|t=2020. COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis.|pdf=|usr=010}} | {{tp|p=32591762|t=2020. COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis.|pdf=|usr=010}} | ||
{{tp|p=32546768|t=2020. Immune status could determine efficacy of COVID-19 therapies.|pdf=|usr=010}} | {{tp|p=32546768|t=2020. Immune status could determine efficacy of COVID-19 therapies.|pdf=|usr=010}} | ||
{{tp|p=32555388|t=2020. Convergent antibody responses to SARS-CoV-2 in convalescent individuals.|pdf=|usr=010}} | {{tp|p=32555388|t=2020. Convergent antibody responses to SARS-CoV-2 in convalescent individuals.|pdf=|usr=010}} | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=32576668|t=2020. A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2.|pdf=|usr=010}} | {{tp|p=32576668|t=2020. A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2.|pdf=|usr=010}} | ||
| Zeile 574: | Zeile 569: | ||
{{tp|p=32597792|t=2020. Reversing immunosenescence for prevention of COVID-19.|pdf=|usr=011}} | {{tp|p=32597792|t=2020. Reversing immunosenescence for prevention of COVID-19.|pdf=|usr=011}} | ||
{{tp|p=32603851|t=2020. Could the COVID-19 pandemic aggravate antimicrobial resistance?|pdf=|usr=011}} | {{tp|p=32603851|t=2020. Could the COVID-19 pandemic aggravate antimicrobial resistance?|pdf=|usr=011}} | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=32545714|t=2020. Reaction Cycles of Halogen Species in the Immune Defense: Implications for Human Health and Diseases and the Pathology and Treatment of COVID-19.|pdf=|usr=011}} | {{tp|p=32545714|t=2020. Reaction Cycles of Halogen Species in the Immune Defense: Implications for Human Health and Diseases and the Pathology and Treatment of COVID-19.|pdf=|usr=011}} | ||
| − | + | ||
{{tp|p=32598880|t=2020. Less expression of CD4(+) and CD8(+) T cells might reflect the severity of infection and predict worse prognosis in patients with COVID-19: Evidence from a pooled analysis.|pdf=|usr=011}} | {{tp|p=32598880|t=2020. Less expression of CD4(+) and CD8(+) T cells might reflect the severity of infection and predict worse prognosis in patients with COVID-19: Evidence from a pooled analysis.|pdf=|usr=011}} | ||
{{tp|p=32579952|t=2020. Hyperferritinemia in critically ill COVID-19 patients - Is ferritin the product of inflammation or a pathogenic mediator?|pdf=|usr=011}} | {{tp|p=32579952|t=2020. Hyperferritinemia in critically ill COVID-19 patients - Is ferritin the product of inflammation or a pathogenic mediator?|pdf=|usr=011}} | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=32561270|t=2020. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.|pdf=|usr=011}} | {{tp|p=32561270|t=2020. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.|pdf=|usr=011}} | ||
| − | + | ||
{{tp|p=32607314|t=2020. Assessing Immune Response to SARS-CoV-2 Infection.|pdf=|usr=011}} | {{tp|p=32607314|t=2020. Assessing Immune Response to SARS-CoV-2 Infection.|pdf=|usr=011}} | ||
| − | + | ||
{{tp|p=32537960|t=2020. A Pathophysiological Perspective on COVID-19's Lethal Complication: From Viremia to Hypersensitivity Pneumonitis-like Immune Dysregulation.|pdf=|usr=011}} | {{tp|p=32537960|t=2020. A Pathophysiological Perspective on COVID-19's Lethal Complication: From Viremia to Hypersensitivity Pneumonitis-like Immune Dysregulation.|pdf=|usr=011}} | ||
| − | + | ||
| − | + | ||
| − | {{ | + | {{ttp|p=32599245|t=2020. Targeting hub genes and pathways of innate immune response in COVID-19: A network biology perspective.|pdf=|usr=011}} |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=32563547|t=2020. Autoinflammatory and autoimmune conditions at the crossroad of COVID-19.|pdf=|usr=011}} | {{tp|p=32563547|t=2020. Autoinflammatory and autoimmune conditions at the crossroad of COVID-19.|pdf=|usr=011}} | ||
{{tp|p=32587094|t=2020. SARS-CoV-2 (COVID-19) structural and evolutionary dynamicome: Insights into functional evolution and human genomics.|pdf=|usr=011}} | {{tp|p=32587094|t=2020. SARS-CoV-2 (COVID-19) structural and evolutionary dynamicome: Insights into functional evolution and human genomics.|pdf=|usr=011}} | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=32569604|t=2020. CD4+T, CD8+T counts and severe COVID-19: A meta-analysis.|pdf=|usr=011}} | {{tp|p=32569604|t=2020. CD4+T, CD8+T counts and severe COVID-19: A meta-analysis.|pdf=|usr=011}} | ||
{{tp|p=32540458|t=2020. Elevated nucleoprotein-induced interferon-gamma release in COVID-19 patients detected in a SARS-CoV-2 enzyme-linked immunosorbent spot assay.|pdf=|usr=011}} | {{tp|p=32540458|t=2020. Elevated nucleoprotein-induced interferon-gamma release in COVID-19 patients detected in a SARS-CoV-2 enzyme-linked immunosorbent spot assay.|pdf=|usr=011}} | ||
{{tp|p=32283140|t=2020. Re: Profile of specific antibodies to SARS-CoV-2: The first report.|pdf=|usr=011}} | {{tp|p=32283140|t=2020. Re: Profile of specific antibodies to SARS-CoV-2: The first report.|pdf=|usr=011}} | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=32543740|t=2020. Dysregulation of the immune response affects the outcome of critical COVID-19 patients.|pdf=|usr=011}} | {{tp|p=32543740|t=2020. Dysregulation of the immune response affects the outcome of critical COVID-19 patients.|pdf=|usr=011}} | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=32540481|t=2020. Can the microcirculatory response to hypoxia be a prognostic factor for Covid-19?|pdf=|usr=011}} | {{tp|p=32540481|t=2020. Can the microcirculatory response to hypoxia be a prognostic factor for Covid-19?|pdf=|usr=011}} | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=32591408|t=2020. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome.|pdf=|usr=011}} | {{tp|p=32591408|t=2020. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome.|pdf=|usr=011}} | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=32576386|t=2020. Deciphering the TCR Repertoire to Solve the COVID-19 Mystery.|pdf=|usr=011}} | {{tp|p=32576386|t=2020. Deciphering the TCR Repertoire to Solve the COVID-19 Mystery.|pdf=|usr=011}} | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=32584597|t=2020. Characterization of the Inflammatory Response to Severe COVID-19 Illness.|pdf=|usr=011}} | {{tp|p=32584597|t=2020. Characterization of the Inflammatory Response to Severe COVID-19 Illness.|pdf=|usr=011}} | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=32538831|t=2020. Herd immunity or suppression strategy to combat COVID-19.|pdf=|usr=011}} | {{tp|p=32538831|t=2020. Herd immunity or suppression strategy to combat COVID-19.|pdf=|usr=011}} | ||
| − | + | ||
{{tp|p=32568186|t=2020. The compelling arguments for the need of microvascular investigation in COVID-19 critical patients.|pdf=|usr=011}} | {{tp|p=32568186|t=2020. The compelling arguments for the need of microvascular investigation in COVID-19 critical patients.|pdf=|usr=011}} | ||
| − | + | ||
| − | + | ||
{{tp|p=32608572|t=2020. Peripheral lymphocyte subset alterations in COVID-19 patients.|pdf=|usr=011}} | {{tp|p=32608572|t=2020. Peripheral lymphocyte subset alterations in COVID-19 patients.|pdf=|usr=011}} | ||
| − | + | ||
| − | + | ||
{{tp|p=32602128|t=2020. Diarrhea and altered inflammatory cytokine pattern in severe COVID-19: impact on disease course and in-hospital mortality.|pdf=|usr=011}} | {{tp|p=32602128|t=2020. Diarrhea and altered inflammatory cytokine pattern in severe COVID-19: impact on disease course and in-hospital mortality.|pdf=|usr=011}} | ||
| − | + | ||
{{tp|p=32563194|t=2020. Serum Cytokine and Chemokine profile in Relation to the Severity of Coronavirus disease 2019 (COVID-19) in China.|pdf=|usr=011}} | {{tp|p=32563194|t=2020. Serum Cytokine and Chemokine profile in Relation to the Severity of Coronavirus disease 2019 (COVID-19) in China.|pdf=|usr=011}} | ||
| − | |||
| − | |||
| − | |||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=32583766|t=2020. Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020.|pdf=|usr=011}} | {{tp|p=32583766|t=2020. Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020.|pdf=|usr=011}} | ||
| − | + | ||
{{tp|p=32595955|t=2020. Expected immune recognition of COVID-19 virus by memory from earlier infections with common coronaviruses in a large part of the world population.|pdf=|usr=011}} | {{tp|p=32595955|t=2020. Expected immune recognition of COVID-19 virus by memory from earlier infections with common coronaviruses in a large part of the world population.|pdf=|usr=011}} | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=32582303|t=2020. Neutrophils, Crucial, or Harmful Immune Cells Involved in Coronavirus Infection: A Bioinformatics Study.|pdf=|usr=011}} | {{tp|p=32582303|t=2020. Neutrophils, Crucial, or Harmful Immune Cells Involved in Coronavirus Infection: A Bioinformatics Study.|pdf=|usr=011}} | ||
| − | {{ | + | {{ttp|p=32595654|t=2020. Interferon-Induced Transmembrane Protein (IFITM3) Is Upregulated Explicitly in SARS-CoV-2 Infected Lung Epithelial Cells.|pdf=|usr=011}} |
| − | + | ||
{{tp|p=32582200|t=2020. Antibody Dependent Enhancement Due to Original Antigenic Sin and the Development of SARS.|pdf=|usr=011}} | {{tp|p=32582200|t=2020. Antibody Dependent Enhancement Due to Original Antigenic Sin and the Development of SARS.|pdf=|usr=011}} | ||
{{tp|p=32574272|t=2020. Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?|pdf=|usr=011}} | {{tp|p=32574272|t=2020. Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?|pdf=|usr=011}} | ||
{{tp|p=32574271|t=2020. The Biology of Lactoferrin, an Iron-Binding Protein That Can Help Defend Against Viruses and Bacteria.|pdf=|usr=011}} | {{tp|p=32574271|t=2020. The Biology of Lactoferrin, an Iron-Binding Protein That Can Help Defend Against Viruses and Bacteria.|pdf=|usr=011}} | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=32574261|t=2020. Humoral Immune Responses in COVID-19 Patients: A Window on the State of the Art.|pdf=|usr=011}} | {{tp|p=32574261|t=2020. Humoral Immune Responses in COVID-19 Patients: A Window on the State of the Art.|pdf=|usr=011}} | ||
{{tp|p=32574260|t=2020. Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection.|pdf=|usr=011}} | {{tp|p=32574260|t=2020. Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection.|pdf=|usr=011}} | ||
{{tp|p=32582743|t=2020. Immune-Inflammatory Parameters in COVID-19 Cases: A Systematic Review and Meta-Analysis.|pdf=|usr=011}} | {{tp|p=32582743|t=2020. Immune-Inflammatory Parameters in COVID-19 Cases: A Systematic Review and Meta-Analysis.|pdf=|usr=011}} | ||
| − | + | ||
| − | + | ||
{{tp|p=32581799|t=2020. Molecular Insights Into SARS COV-2 Interaction With Cardiovascular Disease: Role of RAAS and MAPK Signaling.|pdf=|usr=011}} | {{tp|p=32581799|t=2020. Molecular Insights Into SARS COV-2 Interaction With Cardiovascular Disease: Role of RAAS and MAPK Signaling.|pdf=|usr=011}} | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=32605582|t=2020. Iron metabolism and lymphocyte characterisation during Covid-19 infection in ICU patients: an observational cohort study.|pdf=|usr=011}} | {{tp|p=32605582|t=2020. Iron metabolism and lymphocyte characterisation during Covid-19 infection in ICU patients: an observational cohort study.|pdf=|usr=011}} | ||
| − | + | ||
{{tp|p=32579301|t=2020. Immunity and protection from COVID-19-Environmental mycobacteria play a role.|pdf=|usr=011}} | {{tp|p=32579301|t=2020. Immunity and protection from COVID-19-Environmental mycobacteria play a role.|pdf=|usr=011}} | ||
{{tp|p=32579268|t=2020. SARS-CoV-2-reactive interferon-gamma-producing CD8+ T cells in patients hospitalized with coronavirus disease 2019.|pdf=|usr=011}} | {{tp|p=32579268|t=2020. SARS-CoV-2-reactive interferon-gamma-producing CD8+ T cells in patients hospitalized with coronavirus disease 2019.|pdf=|usr=011}} | ||
{{tp|p=32579244|t=2020. Clinical and biological data on the use of hydroxychloroquine against SARS-CoV-2 could support the role of the NLRP3 inflammasome in the pathogenesis of respiratory disease.|pdf=|usr=011}} | {{tp|p=32579244|t=2020. Clinical and biological data on the use of hydroxychloroquine against SARS-CoV-2 could support the role of the NLRP3 inflammasome in the pathogenesis of respiratory disease.|pdf=|usr=011}} | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=32554697|t=2020. Inactivating Three Interferon Antagonists Attenuates Pathogenesis of an Enteric Coronavirus.|pdf=|usr=011}} | {{tp|p=32554697|t=2020. Inactivating Three Interferon Antagonists Attenuates Pathogenesis of an Enteric Coronavirus.|pdf=|usr=011}} | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=32570166|t=2020. A hypothesis about the role of fetal hemoglobin in COVID-19.|pdf=|usr=011}} | {{tp|p=32570166|t=2020. A hypothesis about the role of fetal hemoglobin in COVID-19.|pdf=|usr=011}} | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=32597823|t=2020. AhR and IDO1 in pathogenesis of Covid-19 and the "Systemic AhR Activation Syndrome:" Translational review and therapeutic perspectives.|pdf=|usr=011}} | {{tp|p=32597823|t=2020. AhR and IDO1 in pathogenesis of Covid-19 and the "Systemic AhR Activation Syndrome:" Translational review and therapeutic perspectives.|pdf=|usr=011}} | ||
{{tp|p=32520467|t=2020. COVID-19: A la recherche des anticorps protecteurs.|pdf=|usr=011}} | {{tp|p=32520467|t=2020. COVID-19: A la recherche des anticorps protecteurs.|pdf=|usr=011}} | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=32499416|t=2020. Sex hormones signal why virus hits men harder.|pdf=|usr=011}} | {{tp|p=32499416|t=2020. Sex hormones signal why virus hits men harder.|pdf=|usr=011}} | ||
Version vom 8. Juli 2020, 18:21 Uhr
coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.
Antibody-dependent enhancement
32361326 2020. Current studies of convalescent plasma therapy for COVID-19 may underestimate risk of antibody-dependent enhancement.
| 32504046 2020. Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures. |
| 32092539 2020. Is COVID-19 receiving ADE from other coronaviruses? |
32268188 ä. It is too soon to attribute ADE to COVID-19
| 31826992 2020. Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry |
| 32317716 ä. The potential danger of suboptimal antibody responses in COVID-19 |
32346094 ä. COVID-19 vaccine design: the Janus face of immune enhancement
32303697 ä. Will we see protection or reinfection in COVID-19?
32438257 2020. SARS-CoV-2 and enhancing antibodies
| 32408068 2020. What about the original antigenic sin of the humans versus SARS-CoV-2? |
32436320 2020. The role of SARS-CoV-2 antibodies in COVID-19: Healing in most, harm at times.
32506725 2020. Dengue Fever, COVID-19 (SARS-CoV-2), and Antibody-Dependent Enhancement (ADE): A Perspective.
32529906 2020. Serological differentiation between COVID-19 and SARS infections.
32380903 2020. Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2.
32426212 2020. Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections.
32526272 2020. Antibody-dependent enhancement and COVID-19: Moving toward acquittal.
Herd immunity
32438622 2020. Dynamics of Population Immunity Due to the Herd Effect in the COVID-19 Pandemic.
32391855 2020. COVID-19 and Postinfection Immunity: Limited Evidence, Many Remaining Questions.
32510562 2020. Long-term and herd immunity against SARS-CoV-2: implications from current and past knowledge.
32418947 2020. Does immune privilege result in recovered patients testing positive for COVID-19 again?
32372779 2020. Do you become immune once you have been infected?
32433946 2020. Herd Immunity: Understanding COVID-19.
32509257 2020. SARS-CoV-2, "common cold" coronaviruses' cross-reactivity and "herd immunity": The razor of Ockham (1285-1347)?
32397700 2020. [Analysis of application of herd immunity as a control strategy for COVID-19].
Neutralizing antibodies
32454513 2020. Human neutralizing antibodies elicited by SARS-CoV-2 infection.
32454512 2020. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2.
32497196 2020. Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients.
| 32073157 2020. Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus?associated illnesses |
32515685 2020. Dynamic surveillance of SARS-CoV-2 shedding and neutralizing antibody in children with COVID-19.
Innate sensing
| 32291557 ä. SARS-CoV-2-encoded nucleocapsid protein acts as a viral suppressor of RNA interference in cells |
32198201 2020. Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors
32374430 2020. DC/L-SIGNs of Hope in the COVID-19 Pandemic
32361001 ä. Bioinformatic analysis and identification of single-stranded RNA sequences recognized by TLR7/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes
32248387 ä. Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of Caution
| 32407669 ä. Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients |
32456409 2020. A theory on SARS-COV-2 susceptibility: reduced TLR7-activity as a mechanistic link between men, obese and elderly.
| 32156572 2020. Viroporins and inflammasomes: A key to understand virus-induced inflammation |
| 32454408 2020. COVID-19 as a STING disorder with delayed over-secretion of interferon-beta. |
32524333 2020. COVID 19: a clue from innate immunity.
32464098 2020. The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19?
integrative work
32205856 2020. COVID-19 infection: the perspectives on immune responses
32359396 ä. A Dynamic Immune Response Shapes COVID-19 Progression
C7064018 ä. Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses
| C7200337 ä. Immunology of COVID-19: current state of the science |
32505227 2020. Immunology of COVID-19: Current State of the Science.
32469225 2020. COVID-19 and the immune system.
| 32436629 2020. High COVID-19 virus replication rates, the creation of antigen-antibody immune complexes and indirect haemagglutination resulting in thrombosis. |
32507543 2020. Spiking Pandemic Potential: Structural and Immunological Aspects of SARS-CoV-2.
| 32504757 2020. Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications. |
32493812 2020. Role of Aging and the Immune Response to Respiratory Viral Infections: Potential Implications for COVID-19.
32470151 2020. The perplexing question of trained immunity versus adaptive memory in COVID-19.
32472706 2020. The Long-Standing History of Corynebacterium Parvum, Immunity and Viruses.
32213336 ä. SARS-CoV-2: virus dynamics and host response
32437933 2020. Viral dynamics in asymptomatic patients with COVID-19.
32407836 2020. Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China.
32498686 2020. Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19).
32514817 2020. Immune Responses to SARS-CoV, MERS-CoV and SARS-CoV-2.
32460144 2020. Altered cytokine levels and immune responses in patients with SARS-CoV-2 infection and related conditions.
32417709 2020. Mechanism of inflammatory response in associated comorbidities in COVID-19.
32444400 2020. COVID-19 and the nicotinic cholinergic system.
32413330 2020. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals.
32514174 2020. A single-cell atlas of the peripheral immune response in patients with severe COVID-19.
32489708 2020. Immune Characteristics of Patients with Coronavirus Disease 2019 (COVID-19).
32396996 2020. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.
| 32454136 2020. The role of IgA in COVID-19. |
| 32526273 2020. A plea for the pathogenic role of immune complexes in severe Covid-19. |
covid modulates the immune system
| 32514047 2020. Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19). |
| 32479746 2020. Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients. |
| 32529952 2020. SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists. |
32364527 2020. Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2
32172672 2020. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses
32315725 ä. Suppressed T cell-mediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan, China
| 32355328 ä. Impaired interferon signature in severe COVID-19 |
32375560 2020. SARS-CoV-2-Induced Immune Dysregulation and Myocardial Injury Risk in China: Insights from the ERS-COVID-19 Study
32376308 ä. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis
| 32236983 2020. Why the immune system fails to mount an adaptive immune response to a COVID-19 infection |
| 32286536 ä. Coronaviruses hijack the complement system |
32463803 2020. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent.
32492165 2020. Clinical and Immune Features of Hospitalized Pediatric Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China.
32514592 2020. Severe COVID-19 is associated with deep and sustained multifaceted cellular immunosuppression.
32456696 2020. COVID-19 patients exhibit less pronounced immune suppression compared with bacterial septic shock patients.
32502135 2020. Reduced monocytic HLA-DR expression indicates immunosuppression in critically ill COVID-19 patients.
32532524 2020. SARS-CoV-2-A Tough Opponent for the Immune System.
32416070 2020. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19.
32513989 2020. The inhibition of IL-2/IL-2R gives rise to CD8(+) T cell and lymphocyte decrease through JAK1-STAT5 in critical patients with COVID-19 pneumonia.
immune cell subpopulations
32282871 ä. Inflammatory Response Cells During Acute Respiratory Distress Syndrome in Patients With Coronavirus Disease 2019 (COVID-19)
32325421 2020. Increased expression of CD8 marker on T-cells in COVID-19 patients
32377375 2020. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing
32346099 ä. High-dimensional immune profiling by mass cytometry revealed immunosuppression and dysfunction of immunity in COVID-19 patients
32339487 2020. Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China
32361250 2020. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients
32228226 2020. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients
32196410 2020. Hypothesis for potential pathogenesis of SARS-CoV-2 infection?a review of immune changes in patients with viral pneumonia
32333914 ä. A possible role for B cells in COVID-19?: Lesson from patients with Agammaglobulinemia
32344320 ä. The clinical course and its correlated immune status in COVID-19 pneumonia
32325129 ä. The profile of peripheral blood lymphocyte subsets and serum cytokines in children with 2019 novel coronavirus pneumonia
32283159 ä. Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19
32227123 ä. Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia
32343510 2020. COVID-19: are T lymphocytes simply watching?
32379887 ä. T cell subset counts in peripheral blood can be used as discriminatory biomarkers for diagnosis and severity prediction of COVID-19
32297671 2020. Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients
32352397 2020. The hemocyte counts as a potential biomarker for predicting disease progression in COVID-19: a retrospective study
32379199 2020. A Typical Case of Critically Ill Infant of Coronavirus Disease 2019 With Persistent Reduction of T Lymphocytes
32296069 2020. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study
32407057 2020. Peripheral lymphocyte subset monitoring in COVID19 patients: a prospective Italian real-life case series.
32297828 2020. Correlation Between Relative Nasopharyngeal Virus RNA Load and Lymphocyte Count Disease Severity in Patients with COVID-19
32370466 2020. Characteristics of peripheral blood leukocyte differential counts in patients with COVID-19
32114745 2020. Characteristics of peripheral blood leukocyte differential counts in patients with COVID-19
32377375 2020. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing
32361250 2020. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients
| 32376308 2020. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis |
32458561 2020. Lymphopenia in COVID-19: Therapeutic opportunities.
32420610 2020. Temporal changes in immune blood cell parameters in COVID-19 infection and recovery from severe infection.
32470153 2020. Characteristics of inflammatory factors and lymphocyte subsets in patients with severe COVID-19.
32474608 2020. Decreased B cells on admission was associated with prolonged viral RNA shedding from respiratory tract in Coronavirus Disease 2019: a case control study.
32483488 2020. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis.
32382776 2020. Signals of Th2 immune response from COVID-19 patients requiring intensive care.
32417210 2020. The underlying changes and predicting role of peripheral blood inflammatory cells in severe COVID-19 patients: A sentinel?
32405080 2020. Decreased T cell populations contribute to the increased severity of COVID-19.
32407466 2020. An inflammatory profile correlates with decreased frequency of cytotoxic cells in COVID-19.
t cell exhaustion
32249845 ä. Fighting COVID-19 exhausts T cells
32479985 2020. Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients.
| 32203188 ä. Functional exhaustion of antiviral lymphocytes in COVID-19 patients |
| 32203186 ä. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients |
| 32203188 2020. Functional exhaustion of antiviral lymphocytes in COVID-19 patients |
| 32203186 2020. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients |
32414395 2020. COVID-19: room for treating T cell exhaustion?
32425950 2020. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19).
nk cells
32382127 ä. NKG2A and COVID-19: another brick in the wall
32344314 2020. Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents
plasmacytoid dendritic cells
32298486 2020. Plasmacytoid lymphocytes in SARS-CoV-2 infection (Covid-19)
antiviral immune response
32280952 ä. Good IgA bad IgG in SARS-CoV-2 infection?
32353870 2020. The many faces of the anti-COVID immune response
32358956 ä. Longitudinal Change of SARS-Cov2 Antibodies in Patients with COVID-19
31981224 2020. Coronavirus infections and immune responses
32198005 2020. A case of COVID-19 and pneumonia returning from Macau in Taiwan: Clinical course and anti-SARS-CoV-2 IgG dynamic
32284614 ä. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19
32355329 ä. SARS-CoV-2-reactive T cells in patients and healthy donors
32346091 ä. Neutralizing antibody response in mild COVID-19
32356908 2020. Mathematical modeling of interaction between innate and adaptive immune responses in COVID-19 and implications for viral pathogenesis
| 32343415 2020. Long-term coexistence of SARS-CoV-2 with antibody response in COVID-19 patients |
32330332 2020. SARS-CoV-2 infection in children - Understanding the immune responses and controlling the pandemic
32267987 2020. Immune responses and pathogenesis of SARS?CoV?2 during an outbreak in Iran: Comparison with SARS and MERS
32348715 2020. B Cells, Viruses, and the SARS-CoV-2/COVID-19 Pandemic of 2020
32382126 ä. Protective humoral immunity in SARS-CoV-2 infected pediatric patients
32200654 2020. Time Kinetics of Viral Clearance and Resolution of Symptoms in Novel Coronavirus Infection
32476607 2020. Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression.
32449333 2020. (+)Ability of the immune system to fight viruses highlighted by cytometry and TCR clonotype assessments: lessons taken prior to COVID-19 virus pandemic outbreak.
32430094 2020. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection.
32467617 2020. Serum IgA, IgM, and IgG responses in COVID-19.
| 32467616 2020. More bricks in the wall against SARS-CoV-2 infection: involvement of gamma9delta2 T cells. |
| 32463434 2020. Metatranscriptomic Characterization of COVID-19 Identified A Host Transcriptional Classifier Associated With Immune Signaling. |
32398307 2020. Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients.
32425634 2020. The dynamics of antibodies to SARS-CoV-2 in a case of SARS-CoV-2 infection.
32383183 2020. A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: A possible reason underlying different outcome between sex.
32521002 2020. Antibody profiles in mild and severe cases of COVID-19.
32399213 2020. Dynamics of peripheral immune cells and their HLA-G and receptor expressions in a patient suffering from critical COVID-19 pneumonia to convalescence.
32515684 2020. Patterns of IgG and IgM antibody response in COVID-19 patients.
| 32425955 2020. Potential SARS-CoV-2 Preimmune IgM Epitopes. |
32439770 2020. T cells found in coronavirus patients 'bode well' for long-term immunity.
| 32473127 2020. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. |
32513850 2020. Early Insights into Immune Responses during COVID-19.
32544611 2020. Development of child immunity in the context of COVID-19 pandemic.
antiviral mediators
32422144 2020. Perforin and resistance to SARS coronavirus 2.
| 32437749 2020. Human Intestinal Defensin 5 Inhibits SARS-CoV-2 Invasion by Cloaking ACE2. |
mediators
32360285 ä. Type I IFN immunoprofiling in COVID-19 patients
| 32376393 ä. Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanisms |
| 32305501 ä. The Potential Role of Th17 Immune Responses in Coronavirus Immunopathology and Vaccine-induced Immune Enhancement |
30715745 2019. (+)Th17 serum cytokines in relation to laboratory?confirmed respiratory viral infection: A pilot study
32414693 2020. Interleukin-6 levels in children developing SARS-CoV-2 infection
| 32421281 2020. Is there relationship between SARS-CoV 2 and the complement C3 and C4? |
32437622 2020. Complement Activation During Critical Illness: Current Findings and an Outlook in the Era of COVID-19.
32475759 2020. IL-6: Relevance for immunopathology of SARS-CoV-2.
immunopathology
32371101 ä. The correlation between SARS-CoV-2 infection and rheumatic disease
32205186 2020. COVID-19 infection and rheumatoid arthritis: Faraway, so close!
32308263 2020. CoViD-19 Immunopathology and Immunotherapy
32320677 ä. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
32161940 ä. Dysregulation of immune response in patients with COVID-19 in Wuhan, China
32282863 ä. Molecular immune pathogenesis and diagnosis of COVID-19
32321823 2020. COVID-19: an Immunopathological View
32273594 ä. COVID-19: immunopathology and its implications for therapy
32303696 ä. Macrophages: a Trojan horse in COVID-19?
| 32376901 ä. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages |
32423059 2020. Recent Insight into SARS-CoV2 Immunopathology and Rationale for Potential Treatment and Preventive Strategies in COVID-19.
32485101 2020. Vascular Endothelial Growth Factor (VEGF) as a Vital Target for Brain Inflammation during the COVID-19 Outbreak.
32423917 2020. COVID-19 as an Acute Inflammatory Disease.
| 32512289 2020. Neutralizing antibodies mediate virus-immune pathology of COVID-19. |
32398875 2020. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19.
32391668 2020. [Dynamic inflammatory response in a critically ill COVID-19 patient treated with corticosteroids].
| 32498376 2020. Neutrophils and Neutrophil Extracellular Traps Drive Necroinflammation in COVID-19. |
32460357 2020. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China.
| 32492530 2020. Aberrant hyperactivation of cytotoxic T-cell as a potential determinant of COVID-19 severity. |
32389590 2020. COVID-19: Unanswered questions on immune response and pathogenesis.
32422146 2020. Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells.
32521376 2020. SARS-CoV-2 (Covid-19): Interferon-epsilon may be responsible of decreased mortality in females.
32470851 2020. Role of oxidized LDL-induced "trained macrophages" in the pathogenesis of COVID-19 and benefits of pioglitazone: A hypothesis.
32454103 2020. Type I astrocytes and microglia induce a cytokine response in an encephalitic murine coronavirus infection.
32398804 2020. Is aberrant CD8+ T cell activation by hypertension associated with cardiac injury in severe cases of COVID-19?
secondary autoimmunity
32292901 2020. Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity
32220633 2020. Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects?
32315487 2020. Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID-19
| 32314313 2020. Is COVID-19 a proteiform disease inducing also molecular mimicry phenomena? |
32389543 ä. COVID-19 and molecular mimicry: The Columbus? egg?
32444414 2020. Antibodies against immunogenic epitopes with high sequence identity to SARS-CoV-2 in patients with autoimmune dermatomyositis.
| 32535095 2020. Molecular mimicry may explain multi-organ damage in COVID-19. |
32535093 2020. Covid-19 and autoimmunity.
32461193 2020. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases.
Thymus
32340873 ä. Reply: Thymopoiesis, inflamm-aging, and COVID-19 phenotype
32317217 ä. Role of thymopoiesis and inflamm-aging in COVID-19 phenotype
Eosinopenia, Eosinophilia
32368728 ä. Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: a retrospective case-control study
32344056 ä. Eosinophil Responses During COVID-19 Infections and Coronavirus Vaccination
32369190 2020. COVID-19, chronic inflammatory respiratory diseases and eosinophils - Observationsfrom reported clinical case series
| 32315429 ä. Eosinophil count in severe coronavirus disease 2019 (COVID-19) |
32315421 ä. Response letter to Eosinophil count in severe coronavirus disease 2019 (COVID-19)
32390402 2020. SARS-CoV-2 and Eosinophilia.
microbiome
32497191 2020. Alterations of the Gut Microbiota in Patients with COVID-19 or H1N1 Influenza.
| 32426999 2020. Gnotobiotic Rats Reveal That Gut Microbiota Regulates Colonic mRNA of Ace2, the Receptor for SARS-CoV-2 Infectivity. |
32432790 2020. Editorial - COVID-19 and the microbiota: new kids on the block.
32442562 2020. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization.
| 32579014 2020. Systemic inflammatory response and thrombosis due to alterations in the gut microbiota in COVID-19. |
32552848 2020. Compassionate use of others' immunity - understanding gut microbiome in Covid-19.
32582138 2020. Intestinal Flora as a Potential Strategy to Fight SARS-CoV-2 Infection.
32582134 2020. Main Clinical Features of COVID-19 and Potential Prognostic and Therapeutic Value of the Microbiota in SARS-CoV-2 Infections.
009
32534627 2020. Have deaths from COVID-19 in Europe plateaued due to herd immunity?
32534626 2020. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study.
32502542 2020. The immune system and COVID-19: Friend or foe?
32398026 2020. Allo-priming as a universal anti-viral vaccine: protecting elderly from current COVID-19 and any future unknown viral outbreak.
32522207 2020. COVID-19: viral-host interactome analyzed by network based-approach model to study pathogenesis of SARS-CoV-2 infection.
32446324 2020. Detection of SARS-CoV-2 in human breastmilk.
32505066 2020. COVID-19: Loss of bridging between innate and adaptive immunity?
32460210 2020. "Therapeutic" facemasks.
32447232 2020. COVID-19: beta-thalassemia subjects immunised?
32445664 2020. COVID-19 as a cause of immune thrombocytopenia.
32446902 2020. Immunoinformatic analysis of the SARS-CoV-2 envelope protein as a strategy to assess cross-protection against COVID-19.
32461674 2020. The non-specific and sex-differential effects of vaccines.
32461671 2020. Innate T cells in COVID-19: friend or foe?
32457522 2020. Dysregulation of type I interferon responses in COVID-19.
32409742 2020. SARS-CoV-2 likes it cool.
32409741 2020. Modulation of immune crosstalk in COVID-19.
32514035 2020. Dissecting antibody-mediated protection against SARS-CoV-2.
32504061 2020. SARS-CoV-2 cross-reactivity in healthy donors.
32504060 2020. Immune evasion via SARS-CoV-2 ORF8 protein?
32504059 2020. Many paths to COVID-19 lymphocyte dysfunction.
32533110 2020. SARS-CoV-2 has a sweet tooth.
32528136 2020. Considering how biological sex impacts immune responses and COVID-19 outcomes.
32415242 2020. A spike with which to beat COVID-19?
32488173 2020. Antimicrobial use, drug-resistant infections and COVID-19.
32427206 2020. Rare and extreme events: the case of COVID-19 pandemic.
32412525 2020. The Myriad Ways in Which COVID-19 Revealed Character.
32528816 2020. Detection and Isolation of SARS-CoV-2 in Serum, Urine, and Stool Specimens of COVID-19 Patients from the Republic of Korea.
32466999 2020. COVID-19 and asthma: To have or not to have T2 inflammation makes a difference?
32533292 2020. Targeting the immunology of coronavirus disease-19: synchronization creates symphony.
32445403 2020. SARS-CoV-2 infection-induced immune responses: Friends or foes?
32434946 2020. SARS-CoV-2 infection protects against rechallenge in rhesus macaques.
32435059 2020. A suspicious role of interferon in the pathogenesis of SARS-CoV-2 by enhancing expression of ACE2.
32528206 2020. COVID-19 and lessons learned from the pandemic wave of meningococcal meningitis (1985-1990).
32387238 2020. Covid-19, induced activation of hemostasis, and immune reactions: Can an auto-immune reaction contribute to the delayed severe complications observed in some patients?
32317245 2020. Ger Rijkers: Persistence of Memory in Times of COVID-19.
32417181 2020. COVID-19: CADD to the rescue.
32215589 2020. Antibodies in Infants Born to Mothers With COVID-19 Pneumonia
32437740 2020. The immunologic status of newborns born to SARS-CoV-2-infected mothers in Wuhan, China.
32510470 2020. Is innate immunity our best weapon for flattening the curve?
32464309 2020. Type I interferons can be detected in respiratory swabs from SARS-Cov-2 infected patients.
32398780 2020. The role of the exposome in promoting resilience or susceptibility after SARS-CoV-2 infection.
32534002 2020. Cancer population may be paradoxically protected from severe manifestations of COVID-19.
| 32461703 2020. Mechanobiology predicts raft formations triggered by ligand-receptor activity across the cell membrane. |
32412125 2020. Androgen sensitivity gateway to COVID-19 disease severity.
32393438 2020. Intelligent classification of platelet aggregates by agonist type.
32444797 2020. BBMRI-ERIC's contributions to research and knowledge exchange on COVID-19.
32415272 2020. Connecting data, tools and people across Europe: ELIXIR's response to the COVID-19 pandemic.
32376989 2020. The VODAN IN: support of a FAIR-based infrastructure for COVID-19.
32335973 2020. Of mice and men: COVID-19 challenges translational neuroscience.
32510005 2020. COVID-19 target: A specific target for novel coronavirus detection.
32437706 2020. Evolution of severe acute respiratory syndrome coronavirus 2 RNA test results in a patient with fatal coronavirus disease 2019: a case report.
32392464 2020. SARS-CoV-2: Combating Coronavirus Emergence.
32473952 2020. SARS-CoV-2: The viral shedding vs infectivity dilemma.
32405281 2020. Sars-CoV-2 and black population: ACE2 as shield or blade?
32524515 2020. Perceived versus proven SARS-CoV-2-specific immune responses in health-care professionals.
31896597 2020. Host AAA+ ATPase TER94 Plays Critical Roles in Building the Baculovirus Viral Replication Factory and Virion Morphogenesis.
32467367 2020. Scientists put survivors' blood plasma to the test.
32496715 2020. [Etiology of epidemic outbreaks COVID-19 on Wuhan, Hubei province, Chinese People Republic associated with 2019-nCoV (Nidovirales, Coronaviridae, Coronavirinae, Betacoronavirus, Subgenus Sarbecovirus): lessons of SARS-CoV outbreak.]
32512133 2020. Poor-sleep is associated with slow recovery from lymphopenia and an increased need for ICU care in hospitalized patients with COVID-19: A retrospective cohort study.
32423901 2020. How covid-19 is accelerating the threat of antimicrobial resistance.
32504123 2020. COVID-19 research: toxicological input urgently needed!
32213337 ä. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study
32360743 ä. Lower detection rates of SARS-COV2 antibodies in cancer patients vs healthcare workers after symptomatic COVID-19
32292530 2020. Respiratory diseases, allergy and COVID-19 infection. First news from Wuhan
32346093 ä. The trinity of COVID-19: immunity, inflammation and intervention
32348636 2020. Hyposalivation as a potential risk for SARS-CoV-2 infection: Inhibitory role of saliva
32235915 ä. COVID-19: a new challenge for human beings
| 32359201 2020. The first, holistic immunological model of COVID-19: implications for prevention, diagnosis, and public health measures |
32376309 2020. Viral kinetics of SARS-CoV-2 in asymptomatic carriers and presymptomatic patients
32388390 2020. The powerful immune system against powerful COVID-19: A hypothesis
32372807 2020. The fever paradox
32220035 2020. SARS-CoV-2: What do we know so far?
32534452 2020. From causes of aging to death from COVID-19.
32489698 2020. COVID-19 Virulence in Aged Patients Might Be Impacted by the Host Cellular MicroRNAs Abundance/Profile.
32401346 2020. SARS-CoV-2 immunogenicity at the crossroads.
32516444 2020. Immunological environment shifts during pregnancy may affect the risk of developing severe complications in COVID-19 patients.
32526483 2020. COVID 19 and brain crosstalks.
32533824 2020. Tuberculosis and type 2 Diabetes Mellitus: an inflammatory danger signal in the time of COVID-19.
32425712 2020. Evidence Supporting a Phased Immuno-physiological Approach to COVID-19 From Prevention Through Recovery.
010
32587367 2020. Potential contribution of increased soluble IL-2R to lymphopenia in COVID-19 patients.
32541836 2020. Systemically comparing host immunity between survived and deceased COVID-19 patients.
32553163 2020. Modulation of Extracellular ISG15 Signaling by Pathogens and Viral Effector Proteins.
32574709 2020. COVID-19 pneumonia: CD8(+) T and NK cells are decreased in number but compensatory increased in cytotoxic potential.
32578831 2020. Human Leukocyte Transcriptional Response to SARS-CoV-2 Infection.
32539816 2020. Response to "COVID-19: room for treating T cell exhaustion?"
32583231 2020. Age-related decline of de novo T cell responsiveness as a cause of COVID-19 severity.
32556942 2020. Severe COVID-19 and aging: are monocytes the key?
32569607 2020. Lymphopenia during the COVID-19 infection: What it shows and what can be learned.
32544911 2020. Strategies to Prevent SARS-CoV-2-Mediated Eosinophilic Disease in Association with COVID-19 Vaccination and Infection.
32585285 2020. Herd Immunity and Vaccination of children for COVID19.
32574694 2020. Relationship between Chest CT manifestations and immune response in COVID-19 patients.
32572527 2020. SARS-CoV-2 viral loads and serum IgA/IgG immune responses in critically ill COVID-19 patients.
32540792 2020. Eosinophil Response Against Classical and Emerging Respiratory Viruses: COVID-19.
32540791 2020. Upper and Lower Airways Functional Examination in Asthma and Respiratory Allergic Deseases. Considerations in the SARS-CoV-2 Post-Pandemic Situation.
32590062 2020. Out of the frying pan and into the fire? Due diligence warranted for ADE in COVID-19.
32581077 2020. COVID-19 Hyperinflammation: What about Neutrophils?
32572247 2020. Sex differences in immune responses in COVID-19.
32572245 2020. Roles for eosinophils and basophils in COVID-19?
32561873 2020. COVID-19 revisiting inflammatory pathways of arthritis.
32589296 2020. COVID-19: A series of important recent clinical and laboratory reports in immunology and pathogenesis of SARS-CoV-2 infection and care of allergy patients.
32584441 2020. Immunology of COVID-19: mechanisms, clinical outcome, diagnostics and perspectives - a report of the European Academy of Allergy and Clinical Immunology (EAACI).
32579026 2020. COVID-19 Related Acute Respiratory Distress Syndrome: Not so Atypical.
32579477 2020. Platelets and Immunity: Going Viral.
32578486 2020. Autophagy/virophagy: a "disposal strategy" to combat COVID-19.
32573711 2020. Platelet Gene Expression and Function in COVID-19 Patients.
32592406 2020. Immune response in children with COVID-19 is characterized by lower levels of T cell activation than infected adults.
32543971 2020. Increased CD4/CD8 ratio as a risk factor for critical illness in coronavirus disease 2019 (COVID-19): a retrospective multicentre study.
32544216 2020. COVID-19 and Crosstalk With the Hallmarks of Aging.
32574708 2020. Mitochondria and Microbiota dysfunction in COVID-19 pathogenesis.
32591762 2020. COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis.
32546768 2020. Immune status could determine efficacy of COVID-19 therapies.
32555388 2020. Convergent antibody responses to SARS-CoV-2 in convalescent individuals.
32576668 2020. A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2.
32597792 2020. Reversing immunosenescence for prevention of COVID-19.
32603851 2020. Could the COVID-19 pandemic aggravate antimicrobial resistance?
32545714 2020. Reaction Cycles of Halogen Species in the Immune Defense: Implications for Human Health and Diseases and the Pathology and Treatment of COVID-19.
32598880 2020. Less expression of CD4(+) and CD8(+) T cells might reflect the severity of infection and predict worse prognosis in patients with COVID-19: Evidence from a pooled analysis.
32579952 2020. Hyperferritinemia in critically ill COVID-19 patients - Is ferritin the product of inflammation or a pathogenic mediator?
32561270 2020. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.
32607314 2020. Assessing Immune Response to SARS-CoV-2 Infection.
32537960 2020. A Pathophysiological Perspective on COVID-19's Lethal Complication: From Viremia to Hypersensitivity Pneumonitis-like Immune Dysregulation.
| 32599245 2020. Targeting hub genes and pathways of innate immune response in COVID-19: A network biology perspective. |
32563547 2020. Autoinflammatory and autoimmune conditions at the crossroad of COVID-19.
32587094 2020. SARS-CoV-2 (COVID-19) structural and evolutionary dynamicome: Insights into functional evolution and human genomics.
32569604 2020. CD4+T, CD8+T counts and severe COVID-19: A meta-analysis.
32540458 2020. Elevated nucleoprotein-induced interferon-gamma release in COVID-19 patients detected in a SARS-CoV-2 enzyme-linked immunosorbent spot assay.
32283140 2020. Re: Profile of specific antibodies to SARS-CoV-2: The first report.
32543740 2020. Dysregulation of the immune response affects the outcome of critical COVID-19 patients.
32540481 2020. Can the microcirculatory response to hypoxia be a prognostic factor for Covid-19?
32591408 2020. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome.
32576386 2020. Deciphering the TCR Repertoire to Solve the COVID-19 Mystery.
32584597 2020. Characterization of the Inflammatory Response to Severe COVID-19 Illness.
32538831 2020. Herd immunity or suppression strategy to combat COVID-19.
32568186 2020. The compelling arguments for the need of microvascular investigation in COVID-19 critical patients.
32608572 2020. Peripheral lymphocyte subset alterations in COVID-19 patients.
32602128 2020. Diarrhea and altered inflammatory cytokine pattern in severe COVID-19: impact on disease course and in-hospital mortality.
32563194 2020. Serum Cytokine and Chemokine profile in Relation to the Severity of Coronavirus disease 2019 (COVID-19) in China.
32583766 2020. Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020.
32595955 2020. Expected immune recognition of COVID-19 virus by memory from earlier infections with common coronaviruses in a large part of the world population.
32582303 2020. Neutrophils, Crucial, or Harmful Immune Cells Involved in Coronavirus Infection: A Bioinformatics Study.
| 32595654 2020. Interferon-Induced Transmembrane Protein (IFITM3) Is Upregulated Explicitly in SARS-CoV-2 Infected Lung Epithelial Cells. |
32582200 2020. Antibody Dependent Enhancement Due to Original Antigenic Sin and the Development of SARS.
32574272 2020. Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?
32574271 2020. The Biology of Lactoferrin, an Iron-Binding Protein That Can Help Defend Against Viruses and Bacteria.
32574261 2020. Humoral Immune Responses in COVID-19 Patients: A Window on the State of the Art.
32574260 2020. Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection.
32582743 2020. Immune-Inflammatory Parameters in COVID-19 Cases: A Systematic Review and Meta-Analysis.
32581799 2020. Molecular Insights Into SARS COV-2 Interaction With Cardiovascular Disease: Role of RAAS and MAPK Signaling.
32605582 2020. Iron metabolism and lymphocyte characterisation during Covid-19 infection in ICU patients: an observational cohort study.
32579301 2020. Immunity and protection from COVID-19-Environmental mycobacteria play a role.
32579268 2020. SARS-CoV-2-reactive interferon-gamma-producing CD8+ T cells in patients hospitalized with coronavirus disease 2019.
32579244 2020. Clinical and biological data on the use of hydroxychloroquine against SARS-CoV-2 could support the role of the NLRP3 inflammasome in the pathogenesis of respiratory disease.
32554697 2020. Inactivating Three Interferon Antagonists Attenuates Pathogenesis of an Enteric Coronavirus.
32570166 2020. A hypothesis about the role of fetal hemoglobin in COVID-19.
32597823 2020. AhR and IDO1 in pathogenesis of Covid-19 and the "Systemic AhR Activation Syndrome:" Translational review and therapeutic perspectives.
32520467 2020. COVID-19: A la recherche des anticorps protecteurs.
32499416 2020. Sex hormones signal why virus hits men harder.
